Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Valneva SE Sponsored ADR VALN

Healthcare  —  Biotechnology
6.14 (0.08) (1.29%) as of 25 Sep
Market cap
$589.8M
P/E
65.3×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Valneva SE Sponsored ADR (VALN) Business Profile

Updated before January 2025

Company Overview

Valneva SE Sponsored ADR (VALN) is a specialty vaccine company that focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. Founded in 1999 and headquartered in Saint-Herblain, France, Valneva has established itself as a key player in the global vaccine industry. The company operates with a mission to protect lives by innovating and delivering vaccines that address unmet medical needs. Valneva is led by a team of experienced professionals, with Thomas Lingelbach serving as the Chief Executive Officer (CEO) and David Lawrence as the Chief Financial Officer (CFO). The company is publicly traded on the NASDAQ under the ticker symbol VALN.

Core Business Segments

Valneva’s business is centered around the development and commercialization of vaccines. The company’s core business segments include:

1. Travel and Endemic Vaccines

Valneva offers vaccines targeting diseases that are prevalent in specific geographic regions or are common among travelers. Key products in this category include:

  • IXIARO®: A vaccine for Japanese encephalitis, primarily targeting travelers and military personnel.
  • DUKORAL®: An oral vaccine for cholera and prevention of diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

2. Emerging and Infectious Disease Vaccines

Valneva is actively involved in developing vaccines for emerging infectious diseases. Notable products and candidates include:

  • VLA1553: A single-shot vaccine candidate for chikungunya virus, currently in late-stage clinical trials.
  • VLA2001: A whole-virus inactivated vaccine for COVID-19, which has been approved in certain markets.

3. Partnered Programs

Valneva collaborates with other pharmaceutical companies and organizations to develop vaccines. For example:

  • Lyme Disease Vaccine (VLA15): Developed in partnership with Pfizer, this vaccine candidate targets Lyme disease and is in advanced clinical trials.

Business Model

Valneva’s business model revolves around innovation, strategic partnerships, and a focus on niche markets. The company generates revenue through:

  • Product Sales: Revenue from the sale of its marketed vaccines, such as IXIARO® and DUKORAL®.
  • Collaborations and Licensing: Income from partnerships with organizations like Pfizer for co-development and licensing agreements.
  • Government Contracts: Valneva secures contracts with governments for vaccine supply, particularly for military and public health programs.

The company invests heavily in research and development (R&D) to expand its vaccine portfolio and address unmet medical needs. By targeting niche markets and leveraging its expertise in vaccine development, Valneva aims to maintain a competitive edge.

Strategic Direction

Valneva has outlined a clear strategic direction to drive growth and innovation:

1. Expansion of Vaccine Portfolio

The company is focused on advancing its pipeline of vaccine candidates, including VLA1553 for chikungunya and VLA15 for Lyme disease. These vaccines have the potential to address significant global health challenges.

2. Geographic Expansion

Valneva aims to expand its presence in key markets, including North America, Europe, and Asia. The approval of VLA2001 in various regions has opened new opportunities for growth.

3. Sustainability Goals

Valneva is committed to sustainability and aims to minimize its environmental impact. The company has implemented measures to reduce waste and energy consumption in its manufacturing processes.

4. Strengthening Partnerships

Collaborations with organizations like Pfizer and the Coalition for Epidemic Preparedness Innovations (CEPI) are central to Valneva’s strategy. These partnerships enable the company to leverage external expertise and resources.

Competitive Landscape

Valneva operates in a highly competitive industry, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Sanofi: A global leader in vaccines, with a broad portfolio of products.
  • GlaxoSmithKline (GSK): Known for its innovative vaccines and strong market presence.
  • Moderna and Pfizer: Leaders in mRNA vaccine technology, particularly for COVID-19.
  • Emergent BioSolutions: Focused on vaccines for infectious diseases and biodefense.

Valneva differentiates itself by focusing on niche markets and developing vaccines for diseases with limited treatment options.

Risk Factors

Valneva faces several risks that could impact its business:

1. Market Dependence

The company relies heavily on the success of its marketed vaccines and pipeline candidates. Any setbacks in clinical trials or regulatory approvals could affect revenue.

2. Supply Chain Disruptions

As a vaccine manufacturer, Valneva is vulnerable to supply chain disruptions, which could delay production and distribution.

3. Competitive Pressure

The vaccine industry is highly competitive, with larger players having greater resources for R&D and marketing.

4. Regulatory Challenges

The approval process for vaccines is stringent and time-consuming. Delays or rejections could hinder Valneva’s growth.

Recent Developments

Valneva has made significant progress in recent years:

  • Approval of VLA2001: The company’s COVID-19 vaccine has been approved in several markets, providing an alternative to mRNA vaccines.
  • Advancement of VLA1553: The chikungunya vaccine candidate has shown promising results in clinical trials and is nearing regulatory submission.
  • Partnership with Pfizer: The collaboration on the Lyme disease vaccine (VLA15) has advanced to late-stage clinical trials, with potential market launch in the coming years.
  • Expansion of Manufacturing Capabilities: Valneva has invested in its manufacturing facilities to meet growing demand for its vaccines.

Investment Considerations

Investors considering Valneva should weigh the following factors:

Strengths

  • Innovative Pipeline: A strong pipeline of vaccine candidates targeting unmet medical needs.
  • Strategic Partnerships: Collaborations with industry leaders like Pfizer enhance credibility and resources.
  • Niche Focus: Targeting underserved markets provides a competitive advantage.

Risks

  • Regulatory Uncertainty: Delays in approvals could impact revenue and growth.
  • Market Competition: Larger players with more resources pose a significant threat.
  • Dependence on Key Products: Reliance on a few marketed vaccines increases vulnerability.

Conclusion

Valneva SE Sponsored ADR (VALN) is a dynamic player in the vaccine industry, with a focus on innovation and addressing unmet medical needs. The company’s strong pipeline, strategic partnerships, and niche market focus position it for future growth. However, investors should consider the risks associated with regulatory challenges and market competition. Overall, Valneva’s commitment to innovation and sustainability makes it a compelling choice for those seeking exposure to the vaccine sector.